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Abstract: Bungarus candidus and Bungarus fasciatus are two species of krait found in 
Southeast Asia. Envenoming by these snakes is often characterized by neurotoxicity and, 
without treatment, causes considerable morbidity and mortality. In this study, the in vitro 
neurotoxicity of each species, and the effectiveness of two monovalent antivenoms and a 
polyvalent antivenom, against the neurotoxic effects of the venoms, were examined in a 
skeletal muscle preparation. Both venoms caused concentration-dependent inhibition of 
indirect twitches, and attenuated responses to exogenous nicotinic receptor agonists, in the 
chick biventer preparation, with B. candidus venom being more potent than B. fasciatus 
venom. SDS-PAGE and western blot analysis indicated different profiles between the venoms. 
Despite these differences, most proteins bands were recognized by all three antivenoms. 
Antivenom, added prior to the venoms, attenuated the neurotoxic effect of the venoms. 
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Interestingly, the respective monovalent antivenoms did not neutralize the effects of the venom 
from the other Bungarus species indicating a relative absence of cross-neutralization. Addition 
of a high concentration of polyvalent antivenom, at the t90 time point after addition of 
venom, partially reversed the neurotoxicity of B. fasciatus venom but not B. candidus 
venom. The monovalent antivenoms had no significant effect when added at the t90 time 
point. This study showed that B. candidus and B. fasciatus venoms display marked in vitro 
neurotoxicity in the chick biventer preparation and administration of antivenoms at high 
dose is necessary to prevent or reverse neurotoxicity. 
Keywords: venom; krait; snake; neurotoxicity; antivenom; Bungarus fasciatus;  
Bungarus candidus 
 
1. Introduction 
Snakes from the Bungarus genus, commonly known as kraits, are nocturnal venomous snakes found 
in many parts of Asia. There are three species of Bungarus found in Malaysia: Bungarus candidus 
(Malayan krait), Bungarus fasciatus (banded krait) and Bungarus flaviceps (red-headed krait) [1]. 
There are two subspecies of Bungarus flaviceps, Bungarus flaviceps flaviceps and Bungarus flaviceps 
baluensis [2]. A high number of krait envenoming cases have been reported in India, Sri Lanka, Thailand 
and Vietnam [3–8]. However, envenoming by kraits is relatively uncommon in Malaysia [9,10]. 
Neurotoxicity characterizes systemic envenoming by kraits [11] and has been attributed to the 
presence of two major classes of neurotoxins in the venom, i.e., presynaptic and postsynaptic 
neurotoxins [7,12,13]. Presynaptic neurotoxins disrupt the release of the neurotransmitter acetylcholine 
from the nerve terminal while postsynaptic neurotoxins inhibit the binding of acetylcholine to the 
nicotinic receptors on the skeletal muscle [12]. Krait venoms have also been shown to contain 
acetylcholinesterase, hyalurodinase and L-amino acid oxidase, which have been hypothesized to 
enhance toxin penetration and contribute to the neurotoxic effect of the venoms [14].  
Untreated respiratory muscle paralysis is the main cause of lethality in krait envenoming [3,15]. 
Morbidities in the form of permanent brain damage due to anoxia, cerebral ataxia, paraplesia, 
mydriasis, problems effecting micturation and causing constipation have also been reported in victims 
of krait bites [4,16]. Treatment options for systemic krait envenoming include administration of 
antivenom and supportive respiratory assistance. High doses of antivenom are often used in krait 
envenomings with limited success in reversing the neurotoxic symptoms [4,17]. The Queen Saovabha 
Memorial Institute (The Thai Red Cross Society; Bangkok, Thailand) produces B. fasciatus antivenom 
(BFAV) and B. candidus antivenom (BCAV) [18]. In addition, the Institute produces Neuro Polyvalent 
Snake antivenom (NPAV) for elapid envenoming which covers not only B. candidus and B. fasciatus 
but also Ophiophagus hannah and Naja kouthia [19]. 
The efficacy of NPAV against Malaysian elapid species and African cobras has been shown 
previously in in vivo experiments [19]. BFAV has been shown to have intraspecific neutralizing effects 
when tested against three species of krait found in Thailand [20]. However, BFAV was not effective 
when administered in patients envenomed by B. candidus [4]. BCAV reduced hospitalization time in 
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patients envenomed by B. candidus in Thailand but there has been no study on the cross-neutralizing 
activity of this antivenom against other krait venoms [18]. The inability of polyvalent antivenoms, 
containing antibodies raised against the venoms of different Bungarus species, to neutralize 
neurotoxicity has been previously documented [5,21]. Geographical variations in venom composition 
have also been found to be a key factor in determining antivenom efficacy [22–24]. Pharmacological, 
biochemical and proteomic studies on various snake species showed that there are differences in the 
activities and composition of venom from the same snake species from different localities [23,25–27] 
In the current study, the in vitro neurotoxic activity of Malaysian B. candidus and B. fasciatus 
venoms was assessed in the indirectly-stimulated chick biventer cervicis nerve-muscle preparation. The 
time to 90% inhibition of the original twitch height (i.e., t90) was used to quantify the neurotoxicity of the 
venoms [28]. The neutralizing capability of two monovalent antivenoms, BCAV and BFAV, and a 
polyvalent antivenom, NPAV, against Malaysian B. candidus and B. fasciatus was also assessed. In 
addition, the cross-neutralising capability of the monovalent antivenoms was evaluated. 
2. Results 
2.1. Chick Biventer Cercivis Nerve-Muscle Preparation 
B. candidus (1 and 10 µg/mL; Figure 1a) and B. fasciatus (1 and 10 µg/mL; Figure 2a) venoms 
abolished indirect twitches of the chick biventer cervicis nerve-muscle preparation. The time required 
for the twitches to be reduced by 90% (i.e., t90) were: B. candidus venom; 1 µg/mL, 61 ± 8 min;  
10 µg/mL, 13 ± 4 min and for B. fasciatus venom; 1 µg/mL, 62 ± 5 min; 10 µg/mL, 22 ± 5 min. 
Repetitive washing with physiological salt solution, commencing at the t90 time point after the addition 
of the venoms (1 µg/mL), did not reverse the neurotoxicity induced by either venom (data not shown). 
B. candidus (1 and 10 µg/mL; Figure 1b) and B. fasciatus (1 and 10 µg/mL; Figure 2b) venoms 
almost completely abolished responses to acetylcholine (ACh) and carbachol (CCh) but not responses 
to potassium chloride (KCl).  
Figure 1. Effect of B. candidus venom on (a) indirect twitches of the chick biventer 
cervicis nerve-muscle preparation and (b) responses to exogenous agonists. *: P < 0.05, 
significantly different from vehicle (n = 3–4, one-way ANOVA for (a) and two-way 
ANOVA for (b)). 
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Figure 2. Effect of B. fasciatus venom on (a) indirect twitches of the chick biventer 
cervicis nerve-muscle preparation and (b) responses to exogenous agonists. *: P < 0.05, 
significantly different from vehicle (n = 3–4, one-way ANOVA for (a) and two-way 
ANOVA for (b)). 
 
2.2. Antivenom Studies 
Pre-incubation of monovalent B. candidus and B. fasciatus antivenoms at 1×, 3× or 5× the 
recommended titres (i.e., 1 mL per 0.6 mg of B. fasciatus venom and 1 mL per 0.4 mg of B. candidus 
venom) prior to the addition of B. candidus (10 µg/mL) or B. fasciatus (10 µg/mL) venoms, caused 
either a marked delay in the time to abolish twitches (i.e., 1× each antivenom) or prevented twitch 
inhibition (i.e., 3× and 5× concentrations of each antivenom) (Figure 3a,b). 
Figure 3. Effect of prior addition of increasing concentrations of (a) B. candidus 
antivenom (BCAV) on the neurotoxic effects of B. candidus venom (10 µg/mL) or (b) B. 
fasciatus antivenom (BFAV) on the neurotoxic effects of B. fasciatus venom (10 µg/mL) 
in the chick biventer cervicis nerve-muscle preparation. *: P < 0.05, significantly different 
than the respective venom alone (n = 3–4, one-way ANOVA). 
 
Pre-incubation with 3× the recommended titre of NPAV also markedly attenuated the reduction in 
twitch height induced by B. candidus (10 µg/mL) and B. fasciatus (10 µg/mL) venoms (Figure 4a,b). 
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Figure 4. Effect of prior addition of increasing concentrations of Neuro Polyvalent antivenom 
(NPAV) on the neurotoxic effects of (a) B. candidus venom (10 µg/mL) or (b) B. fasciatus 
venom (10 µg/mL) in the chick biventer cervicis nerve-muscle preparation. *: P < 0.05, 
significantly different than the respective venom alone (n = 3–4, one-way ANOVA). 
 
The prior addition of monovalent BFAV (3× titre) was unable to prevent the reduction in twitches 
induced by the subsequent addition of B. candidus venom (10 µg/mL) (Figure 5). Similarly, the prior 
addition of monovalent BCAV (3× titre) was unable to prevent the reduction in twitches induced by 
the subsequent addition of B. fasciatus venom (10 µg/mL) (Figure 5). 
Figure 5. Effect of prior addition of B. candidus antivenom (3×; BCAV) or B. fasciatus 
antivenom (3×; BFAV) on the neurotoxic effects of B. fasciatus (10 µg/mL; n = 3) or  
B. candidus (10 µg/mL; n = 3) venoms, respectively, in the chick biventer cervicis  
nerve-muscle preparation.  
  
Neither monovalent antivenom (3× recommended titre) significantly restored twitch height when 
added at the t90 time point. However, NPAV produced a small but significant increase in twitch height 
for B. fasciatus venom when added at the t90 time point i.e., approximately 20% recovery of twitch 
height (Figure 6b). 
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Figure 6. Effect of (a) B. candidus antivenom (3×; BCAV) or Neuro Polyvalent antivenom 
(3×; NPAV), added at the t90 time point, on the neurotoxic effects of B. candidus  
(10 µg/mL) venom or (b) B. fasciatus antivenom (3×; BFAV) or Neuro Polyvalent 
antivenom (3×; NPAV), added at the t90 time point, on the neurotoxic effects of B. fasciatus 
(10 µg/mL) venom in the chick biventer cervicis nerve-muscle preparation. *: P < 0.05, 
significantly different from zero, one sample t-test (n = 3). 
 
2.3. SDS-PAGE and Western Blot 
SDS-PAGE analysis showed that B. candidus and B. fasciatus venoms consist of proteins of MW 
ranging from 10 to 75 kDa (Figure 7). Non-reduced venoms possessed a greater number of protein 
bands compared to reduced venoms. Thick and high intensity bands clumped together were observed 
in the MW range of 10–15 kDa in non-reduced B. candidus venom and 15–20 kDa in non-reduced B. 
fasciatus venom. No protein band was observed within the range of 20–50 kDa in reduced B. fasciatus 
venom. A single band was observed within the 150–250 kDa range in non-reduced B. fasciatus venom. 
Figure 7. SDS-PAGE of venoms on a 12% gel. Venoms were treated in reducing and  
non-reducing buffer prior to loading and stained with Coomassie blue. M indicates the 
protein marker lane, BC(R) indicates B. candidus venom treated with reducing buffer and 
BC(NR) indicates B. candidus venom treated with non reducing sample buffer. BF(R) 
indicates B. fasciatus venom treated with reducing buffer and BF(NR) indicates B. 
fasciatus venom treated with non-reducing sample buffer. 
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Western blotting of the gels with BCAV, BFAV or NPAV showed differences in the 
immunoreactivity profile against some protein bands in the venoms (Figure 8). Proteins belonging to 
the 15–50 kDa and 100–150 kDa ranges, previously not detected during SDS-PAGE, were identified 
by western blotting. The monovalent antivenoms were able to react with most of the protein bands 
from their respective species within the 15–20 kDa and 100–250 kDa weight ranges.  
Figure 8. SDS-PAGE and western blot of venoms. M indicates the protein marker lane, 
BC (B. candidus) and BF (B. fasciatus) indicate reduced venoms in 12% gel. BCAV: 
reduced venoms incubated with monovalent B. candidus antivenom; BFAV: reduced venoms 
incubated with B. fasciatus antivenom; NPAV: reduced venoms incubated with neuro 
polyvalent antivenom. X indicates protein bands that were not detected based in the  
SDS-PAGE and in the membrane that was treated with the venom’s monovalent antivenom. 
 
3. Discussion 
This study showed that both B. candidus and B. fasciatus venoms cause marked in vitro 
neurotoxicity. Based on t90 values, B. candidus was more potent than B. fasciatus venom. These 
studies are comparable to the results of previous lethality studies [14], although we caution against 
comparing the results of in vitro experiments to in vivo experiments. Contractile responses to ACh and 
CCh, but not KCl, were significantly attenuated by both venoms, indicating the likely presence of 
postsynaptic neurotoxins and an apparent lack of myotoxic activity. Repetitive washing with 
physiological salt solution did not reverse the neurotoxic effects of either venom, suggesting that the 
toxins inducing this effect were irreversible or pseudo-irreversible. It also supports the previous findings 
on the detection and isolation of potent presynaptic and postsynaptic neurotoxins in B. candidus and  
B. fasciatus venoms [7,15,29]. Pseudo-irreversible antagonism occurs when the agonist (e.g., 
acetylcholine released from the nerve terminal) and antagonist (e.g., post-synaptic neurotoxins in the 
venom) compete for the receptor (e.g., skeletal muscle nicotinic receptor) but the antagonist dissociates 
from the receptor so slowly (i.e., slow off-rate antagonist) that the agonist cannot achieve equilibrium 
with the receptor. 
SDS-PAGE analysis showed that both venoms consist of a complex mixture of proteins with 
different molecular weights. The lower number of protein bands in reduced venoms compared to  
non-reduced venoms indicates the presence of proteins complexes in the venoms. Reduced presynaptic 
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phospholipase and three-finger toxins in krait venoms are likely to be responsible for the higher 
number of bands within the 10–15 kDa range when the venoms are reduced [13,30]. 
Western blotting against BCAV, BFAV and NPAV showed that there are differences in the 
immunoreactivity of protein components in the venoms. The absence of several bands in the blots 
indicate that not all proteins in the venoms react with antivenoms and these components may 
contribute to the lack of effectiveness of the antivenoms. However, a single band in SDS-PAGE may 
contain several proteins even after fractionation [31]. Therefore, there is a possibility that 
immunoreactive proteins may be masked with proteins that do not react with the antivenom within the 
same band. In addition, caution should be displayed when extrapolating the data from SDS-PAGE and 
western blot experiments as the bands correspond to denatured proteins and we cannot exclude the 
possibility that the antivenoms may recognize some proteins in vivo but not the western blot. 
The efficacy of the antivenoms used in the current study have not previously been examined  
in vitro. Interestingly, a relatively high concentration (i.e., at least three times the recommended titre) 
of all antivenoms was required to prevent attenuation of indirect twitches. This may indicate that the 
composition of the Malaysian krait venoms are slightly different than the venoms used in the 
production of the antivenoms. Indeed, differences in the composition/activity of B. candidus and  
B. fasciatus venoms from different populations have been previously reported [7,32]. It is also possible 
that higher concentrations of antivenoms are required due to the lower immunogenicity of low 
molecular neurotoxins [22,33] which are responsible for the in vitro effects. The antivenoms were also 
largely ineffective, even at high concentrations, when added at the t90 time point. The inability of the 
antivenoms to markedly reverse the neurotoxic effects, after venom administration, is likely to be 
related to the irreversible effects of presynaptic neurotoxins in the venoms [34].  
The lack of effect of the monovalent antivenoms against the venom of the other krait species (i.e., 
BCAV against B. fasciatus venom, and vice versa) indicates a relative absence of cross-neutralization. 
This finding supports clinical observations where no beneficial outcome was seen when B. fasciatus 
antivenom was administered to patients envenomed by B. candidus [4] despite observed neutralization 
in animals [20]. The absence of cross-neutralization by either monovalent antivenom indicates that 
interspecies variation exists in the composition of the neurotoxins in the venoms. Therefore, it is 
possible that the immunoreactivity of some proteins observed in the western blot was due to binding of 
the antivenoms to invariant amino acid positions in the toxins [35] or at a position that had been 
modified during sample pretreatment [36]. Indeed, phospholipase A2 neurotoxins and three finger 
toxin families are known to have similar invariant structural arrangements within the families [37,38].  
4. Experimental Section  
4.1. Venoms and Antivenoms 
B. candidus and B. fasciatus venoms were a gift from Mr. Zainuddin Ismail (Perlis, Northwest 
Peninsular Malaysia). The snakes were collected in states of Kedah and Perlis, Northwest Peninsular 
Malaysia. The venoms from 10 snakes from each species were obtained and pooled by allowing snakes 
to bite plastic containers covered with Parafilm. After collection, the pooled venoms were transported 
on ice back to the laboratory, frozen at −80 °C and then freeze-dried. Freeze-dried venom samples 
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were weighed, labeled and stored at −20 °C prior use. When required, the venoms were weighed and 
dissolved in Milli-Q water. B. candidus antivenom (Lot No.:BC00112) and B. fasciatus antivenom 
(Lot No.:BKC0108), and Neuro Polyvalent antivenom (Lot No.:KP00109) were purchased from 
Queen Saovabha Red Cross Society, Bangkok, Thailand. The freeze-dried antivenoms were dissolved 
with pharmaceutical grade water supplied by the manufacturer. The dissolved antivenoms were stored 
at 4 °C prior to use. 
4.2. Chemicals and Drugs 
The following were purchased from Sigma Aldrich (St. Louis, MO, USA): acetylcholine (ACh), 
carbamylcholine chloride (CCh), d-tubocurarine, bovine serum albumin. 
4.3. Protein Quantification by Bicinchoninic Acid Assay (BCA) 
Protein quantification was performed as instructed by the manufacturer (Pierce Biotechnology, 
Rockford, IL, USA). Approximately 25 µL of sample or standard was loaded onto a 96-well plate in 
triplicate, then 200 µL reagent buffer mix was added to each well. The plate was incubated at 37 °C for 
30 min, then read at 562 nm using a plate reader spectrophotometer (VersaMax Elisa Microplate 
reader, Molecular Device, Sunnyvale, CA, USA). The protein concentration was determined from the 
standard curve. 
4.4. Indirectly-Stimulated Chick Biventer Cervicis Nerve-Muscle Preparation (CBCM) 
The experiments using this preparation were conducted using a method previously described [21,23,35]. 
Male chicks (5–12 days old) were killed by CO2 inhalation before the biventer nerve-muscle preparations 
were dissected and mounted in 5 mL organ baths aerated with carbogen (5% CO2 and 95% O2). The 
organ baths were filled with physiological salt solution of the following composition: NaCl, 118.4 mM; 
KCl, 4.7 mM; MgSO4, 1.2 mM KH2PO4, 1.2 mM; CaCl2, 2.5 mM; NaHCO3, 25 mM and glucose, 
11.1 mM. The tissues were stimulated every 10 s with pulses of 0.2 ms duration at a supramaximal 
voltage (10–20 V) using a Grass S88 stimulator attached to silver ring electrodes. Indirect stimulation 
of the tissues was confirmed by the abolishment of twitches by d-tubocurarine (10 µM), which was 
then washed out until twitches were restored. In the absence of electrical stimulation, responses to 
acetylcholine (ACh; 1 mM for 30 s), carbachol (CCh; 20 µM for 60 s) and KCl (40 mM for 30 s) were 
obtained. Responses were recorded on a PowerLab (ADInstruments, Bella Vista, NSW, Australia). 
For antivenom studies, antivenom was added into the organ bath 10 min prior to the addition of 
venom or after the addition of venom at the t90 time point. 
4.5. Sodium Dodecyl Sulphate Polyacylamide Gel Electrophoresis (SDS-PAGE) 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was conducted in 12% 
polyacrylamide gel by using the method previously described [39]. The gels were then stained with 
Coomassie blue and de-stained by using 10% acetic acid in water. Kaleidoscope Protein Marker  
(Bio-Rad, Hercules, CA, USA) was used in the gel for molecular weight protein marker. The gel was 
scanned using the ChemiDoc XRS Imaging System (BioRad, Hercules, CA, USA). 
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4.6. Western-Blot 
Venoms (10 µg) were loaded and electrophoresed in 12% separating SDS-PAGE gel with 5% 
stacking gel as described in section 4.5. The venom was transferred onto polyvinylidene difluoride 
(PVDF) membrane (Merck Milipore, Billerica, MA, USA) by semi-dry electroblotting (BioRad, 
Hercules, CA, USA) at 10 V for 45 min. The membrane was then blocked in Tris-buffered saline with 
1% Tween 20 (TBST) buffer (20 mM Tris, 0.5 M NaCl and 0.5% Tween-20) supplemented with 5% 
skim milk for 1 h at room temperature. Primary antibodies (i.e., Thai Red Cross Society’s B. fascistus 
antivenom, B. candidus antivenom or Neuro Polyvalent antivenom diluted 1:500 fold in TBST with 
5% skim milk) were then added and the membrane incubated overnight at 4 °C. The membrane was 
then washed three times for 15 min with TBST buffer. Secondary antibody (i.e., goat anti-horse IgG 
secondary antibody conjugated with horseradish peroxidase (Santa Cruz Biotechnology Inc., Dallas, 
TX, USA) diluted in 1:5000 with TBST buffer with 5% skim milk) was added to the membrane and 
left for 45 min at room temperature. The membrane was then washed three times for 10 min and the 
membrane incubated with Immobilon western chemiluminiscent (ECL) substrate (Merck Miliprore, 
Billerica, MA, USA) as described by the manufacturer. After incubation, the excess ECL reagent was 
removed and the membrane was exposed to x-ray film (Fujifim, Melbourne, Australia) to visualize the 
bands. The film and the membrane were scanned using the ChemiDoc XRS Imaging System (BioRad, 
Hercules, CA, USA). 
4.7. Data Analysis 
Changes in twitch height are expressed as a percentage of the original twitch height (i.e., prior to the 
addition of venom). Changes in the magnitude of contractile responses to exogenous agonists are 
expressed as a percentage of the original response to the agonist prior to the addition of venom. Data 
were analyzed by using a one-way analysis of variance (ANOVA) or two-way ANOVA followed by 
Dunnet's multiple comparison test (GraphPad Prism 6, La Jolla, CA, USA). 
5. Conclusions 
In conclusion, we found that Malaysian Bungarus candidus and Bungarus fasciatus venoms display 
marked in vitro neurotoxicity with B. candidus being slightly more potent than B. fasciatus. The 
neurotoxic effect of these venoms was attenuated by their respective monovalent antivenoms, albeit at 
higher concentrations than recommended, but there was limited cross neutralization. The apparent 
presence of potent, but low immunogenic neurotoxins, requires more investigation to identify methods 
to enhance the efficacy of the antivenoms. The data suggests that the non-specific Neuro Polyvalent 
antivenom may be useful for the treatment of B. candidus or B. fasciatus envenoming if the biting 
species cannot be determined or the specific monovalent antivenom is unavailable. Given the 
irreversible nature of the neurotoxic effects of the venoms, it would appear that early administration of 
the appropriate antivenom would be advantageous. A clinical trial is needed to assess the appropriate 
dose of antivenom to be use in the treatment for envenoming by these Malaysian species. This study 
also showed that there is a need for further work to explore geographical variation of the venoms from 
these species.  
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